Minimally Invasive Biopsy Techniques Market Size, Share, Growth, and Industry Analysis, By Type (Tests, Kits & Consumables, Instruments), By Application (Clinical, Therapeutic), Regional Insights and Forecast to 2035

Minimally Invasive Biopsy Techniques Market Overview

The Minimally Invasive Biopsy Techniques Market is experiencing substantial expansion due to the growing prevalence of cancer, increasing preference for outpatient diagnostic procedures, and rapid advancements in imaging technologies. More than 19 million cancer cases are diagnosed globally every year, creating significant demand for accurate biopsy procedures. Over 68% of hospitals worldwide currently utilize minimally invasive biopsy systems for breast, prostate, lung, and liver diagnostics. Image-guided biopsy procedures account for nearly 61% of all tissue sampling interventions globally. 

The USA represents a major contributor to the Minimally Invasive Biopsy Techniques Market Share due to advanced healthcare infrastructure and high cancer screening volumes. More than 1.9 million new cancer diagnoses are reported annually in the United States. Approximately 39 million mammography procedures are conducted each year, while nearly 72% of breast biopsies are performed using minimally invasive technologies. More than 6,000 ambulatory surgical centers across the country utilize image-guided biopsy systems. Ultrasound-guided biopsy procedures account for nearly 44% of minimally invasive interventions in the USA healthcare sector. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 64% of oncology centers reported increased demand for image-guided biopsy procedures, while cancer screening participation rose by 37% globally. Approximately 58% of physicians prefer minimally invasive diagnostic procedures because recovery periods are nearly 47% shorter compared to traditional surgical biopsies.
• Major Market Restraint: Approximately 42% of small healthcare facilities face financial limitations for acquiring advanced biopsy systems, while 36% of low-income healthcare institutions lack access to robotic-assisted biopsy platforms. Around 29% of hospitals experience operational delays caused by equipment shortages and imaging limitations.
• Emerging Trends: Nearly 48% of healthcare providers are implementing AI-assisted imaging systems for biopsy guidance, while robotic-assisted biopsy adoption increased by 33% globally. MRI-guided biopsy utilization expanded by approximately 27% in high-risk oncology diagnostics and precision tissue sampling procedures.
• Regional Leadership: North America contributes approximately 41% of total minimally invasive biopsy procedures worldwide, while Europe accounts for nearly 29%. Asia-Pacific represents around 24% of global adoption due to increasing cancer screening initiatives and expanding healthcare infrastructure investments.
• Competitive Landscape: Approximately 54% of industry participants are focusing on AI-integrated biopsy systems, while 38% prioritize robotic-assisted technologies. Nearly 31% of manufacturers expanded partnerships with diagnostic imaging centers to strengthen Minimally Invasive Biopsy Techniques Market Opportunities globally.
• Market Segmentation: Core needle biopsy systems contribute nearly 46% of procedural demand, while vacuum-assisted biopsy systems account for around 28%. Hospitals represent approximately 57% of end-user adoption, followed by diagnostic imaging centers contributing nearly 26% of total procedures.
• Recent Development: Nearly 35% of major companies introduced AI-enabled biopsy navigation systems, while 22% launched portable ultrasound-guided biopsy devices. Around 31% of healthcare facilities upgraded digital imaging platforms for improved minimally invasive oncology diagnostics and procedural accuracy.

Minimally Invasive Biopsy Techniques Market Latest Trends

The Minimally Invasive Biopsy Techniques Market Analysis indicates strong growth in image-guided oncology diagnostics across healthcare institutions. Ultrasound-guided biopsy procedures currently account for more than 43% of total image-guided interventions because of shorter procedural durations and improved patient comfort. MRI-guided biopsy technologies are increasingly utilized in breast and prostate cancer diagnostics, particularly among high-risk patient groups. More than 52% of tertiary hospitals now integrate digital imaging systems into biopsy workflows to improve lesion targeting accuracy. 

Technological innovation remains a significant factor influencing Minimally Invasive Biopsy Techniques Market Trends. Nearly 48% of newly installed biopsy platforms include AI-enabled lesion detection and navigation support systems. Portable biopsy devices are gaining rapid adoption in ambulatory surgical centers where procedural efficiency is prioritized. Vacuum-assisted biopsy technologies contribute approximately 28% of breast biopsy procedures globally due to improved tissue extraction capabilities. More than 61% of healthcare providers report increasing demand for same-day diagnostic procedures and shorter patient recovery periods. 

Minimally Invasive Biopsy Techniques Market Dynamics

DRIVER

"Rising prevalence of cancer and demand for early diagnostics"

The increasing global burden of cancer remains the primary growth driver for the Minimally Invasive Biopsy Techniques Market. More than 19 million new cancer cases are diagnosed annually worldwide, creating strong demand for accurate and minimally invasive diagnostic procedures. Breast cancer screening participation increased by approximately 39% globally, while prostate cancer diagnostic procedures expanded by nearly 26%. Hospitals and oncology centers increasingly prefer minimally invasive biopsy procedures because they reduce hospitalization durations by approximately 47% and lower post-procedural complications by nearly 31%. 

RESTRAINTS

"High equipment costs and limited accessibility"

The Minimally Invasive Biopsy Techniques Market faces major restraints associated with the high cost of advanced imaging and robotic-assisted biopsy systems. Approximately 42% of smaller healthcare facilities lack sufficient budgets to procure MRI-guided biopsy technologies. Nearly 36% of healthcare providers in developing regions continue to depend on conventional biopsy methods because of limited imaging infrastructure. Maintenance expenditures for advanced biopsy systems increased by around 24% across specialized healthcare institutions. 

OPPORTUNITY

"Expansion of AI-integrated and robotic-assisted biopsy systems"

Artificial intelligence integration and robotic-assisted technologies are creating substantial Minimally Invasive Biopsy Techniques Market Opportunities. Nearly 48% of healthcare institutions are investing in AI-powered lesion detection and navigation systems. Robotic-assisted biopsy procedures improved tissue targeting precision by approximately 34% in advanced oncology diagnostics. Portable biopsy systems experienced nearly 29% higher adoption in outpatient diagnostic centers and ambulatory surgical facilities. Precision medicine programs and personalized oncology treatment initiatives continue to generate strong demand for highly accurate tissue sampling technologies. 

CHALLENGE

"Operational complexity and shortage of skilled specialists"

The Minimally Invasive Biopsy Techniques Market Outlook is challenged by procedural complexity and shortages of experienced healthcare professionals. Approximately 38% of healthcare facilities report difficulties recruiting skilled interventional radiologists and biopsy technicians. Training requirements for robotic-assisted biopsy systems increased by nearly 27% due to advanced software integration and imaging protocols. Around 32% of hospitals experience workflow inefficiencies while integrating AI-enabled biopsy systems into existing diagnostic infrastructure. 

Minimally Invasive Biopsy Techniques Market Segmentation

The Minimally Invasive Biopsy Techniques Market segmentation is categorized by type and application, reflecting the growing adoption of advanced diagnostic technologies across healthcare systems. By type, the market includes Tests, Kits & Consumables, and Instruments, each contributing significantly to biopsy workflow efficiency and diagnostic precision. Instruments account for nearly 46% of procedural utilization due to rising adoption of image-guided and robotic-assisted technologies. 

Download Free Sample to learn more about this report.

BY TYPE

Tests: The Tests segment represents a major portion of the Minimally Invasive Biopsy Techniques Market due to the increasing requirement for rapid and precise tissue diagnostics. Diagnostic testing associated with minimally invasive biopsy procedures is expanding significantly because healthcare providers prioritize early-stage disease detection and personalized treatment planning. More than 61% of cancer diagnosis protocols globally now involve image-guided biopsy testing procedures. Breast cancer testing procedures account for approximately 39% of total minimally invasive biopsy-related diagnostics, followed by lung and prostate cancer applications. Advanced molecular testing linked with biopsy tissue analysis increased by nearly 33% across oncology laboratories and pathology centers. The growing demand for genomic profiling and biomarker testing has strengthened the adoption of minimally invasive tissue testing technologies. Approximately 47% of pathology laboratories utilize automated biopsy tissue analysis systems to improve reporting speed and diagnostic accuracy. 

Kits & Consumables: The Kits & Consumables segment holds a substantial share in the Minimally Invasive Biopsy Techniques Market Analysis due to the recurring requirement for disposable medical products during biopsy procedures. Biopsy needles, vacuum-assisted consumables, syringes, localization wires, and specimen collection products are extensively utilized across hospitals and outpatient diagnostic centers. More than 72% of minimally invasive biopsy procedures require single-use consumables to maintain procedural safety and infection control standards. Core needle biopsy consumables account for nearly 41% of total product utilization globally. The increasing volume of cancer screening procedures significantly boosts demand for biopsy consumables. Approximately 39 million mammography procedures are conducted annually in the United States, creating strong demand for breast biopsy kits and tissue sampling accessories. 

Instruments: The Instruments segment dominates the Minimally Invasive Biopsy Techniques Market Share because of the growing adoption of advanced imaging systems, robotic-assisted platforms, and automated tissue sampling devices. Instruments contribute approximately 46% of total market procedural utilization due to increasing installation of ultrasound-guided, MRI-guided, CT-guided, and stereotactic biopsy systems across healthcare institutions. Ultrasound-guided biopsy devices alone account for nearly 43% of image-guided biopsy procedures globally because of lower operational complexity and faster procedure times. Hospitals and specialty oncology centers continue to invest heavily in technologically advanced biopsy instruments capable of improving targeting precision and reducing procedural complications. More than 48% of newly installed biopsy systems include AI-assisted lesion detection software and automated navigation capabilities. Robotic-assisted biopsy instruments improved procedural targeting accuracy by approximately 34% in prostate and lung cancer diagnostics. 

BY APPLICATION

Clinical: The Clinical application segment represents the largest share of the Minimally Invasive Biopsy Techniques Market due to increasing demand for cancer diagnosis, disease monitoring, and outpatient tissue sampling procedures. Clinical applications account for approximately 64% of total minimally invasive biopsy procedures worldwide. Breast cancer diagnostics remain the leading clinical application, contributing nearly 38% of procedural volumes globally. Lung, prostate, liver, and kidney biopsy procedures also experienced significant expansion because of rising chronic disease prevalence and increasing physician preference for image-guided diagnostics. Hospitals, pathology laboratories, and oncology centers increasingly utilize minimally invasive biopsy procedures to improve diagnostic precision while reducing patient hospitalization periods. More than 58% of clinicians recommend image-guided biopsy procedures instead of surgical interventions because minimally invasive approaches reduce procedural complications by nearly 31%. 

Therapeutic: The Therapeutic application segment is gaining substantial importance in the Minimally Invasive Biopsy Techniques Market as healthcare providers increasingly combine diagnostic and interventional treatment procedures. Therapeutic biopsy applications are widely utilized in oncology management, targeted drug delivery planning, and minimally invasive lesion treatment protocols. Approximately 36% of advanced oncology procedures now involve therapeutic biopsy-guided interventions aimed at improving treatment precision and reducing surgical complexity. Image-guided therapeutic procedures are expanding significantly across liver, lung, and prostate oncology treatments. More than 41% of interventional radiology departments utilize biopsy-guided procedures for tumor ablation planning and targeted therapy administration. 

Minimally Invasive Biopsy Techniques Market Regional Outlook

The Minimally Invasive Biopsy Techniques Market demonstrates strong regional diversification driven by healthcare infrastructure development, cancer screening programs, and technological advancements in diagnostic imaging systems. North America holds approximately 41% of the global market share due to widespread adoption of robotic-assisted biopsy technologies and high outpatient diagnostic volumes. Europe contributes nearly 29% share, supported by increasing investments in precision oncology and advanced pathology integration. Asia-Pacific accounts for approximately 24% of global procedural utilization because of rising healthcare expenditure, expanding cancer awareness programs, and rapid adoption of image-guided diagnostics across China, Japan, and India. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Minimally Invasive Biopsy Techniques Market Share with approximately 41% contribution to global procedural utilization. The region benefits from advanced healthcare infrastructure, high cancer screening participation, and extensive integration of image-guided biopsy systems across hospitals and ambulatory surgical centers. More than 1.9 million new cancer diagnoses are reported annually in the United States alone, significantly increasing demand for minimally invasive diagnostic procedures. Approximately 72% of breast biopsy interventions in North America are performed using minimally invasive technologies instead of surgical biopsies. The region demonstrates strong adoption of ultrasound-guided, MRI-guided, and stereotactic biopsy systems. Ultrasound-guided procedures account for nearly 44% of minimally invasive interventions across oncology centers in North America because of shorter procedure times and lower operational complexity. MRI-guided biopsy systems also experienced approximately 27% higher procedural adoption across tertiary healthcare institutions specializing in breast and prostate cancer diagnostics.

EUROPE

Europe accounts for nearly 29% of the global Minimally Invasive Biopsy Techniques Market Share, supported by advanced public healthcare systems, increasing cancer awareness initiatives, and strong investments in precision medicine technologies. More than 3.7 million new cancer cases are diagnosed annually across Europe, creating substantial demand for minimally invasive diagnostic procedures. Breast cancer screening participation exceeds 63% across major European countries, significantly increasing procedural demand for vacuum-assisted and stereotactic biopsy systems. Hospitals and oncology centers across Europe increasingly prefer minimally invasive biopsy technologies because these procedures reduce hospitalization periods by approximately 46% and lower post-operative complications by nearly 31%. Around 57% of European healthcare institutions now utilize image-guided biopsy systems integrated with digital pathology platforms. Ultrasound-guided biopsy procedures contribute approximately 42% of total interventions within the region due to their operational efficiency and reduced procedural risk. 

GERMANY Minimally Invasive Biopsy Techniques Market

Germany represents one of the leading contributors to the Europe Minimally Invasive Biopsy Techniques Market, accounting for approximately 22% of regional procedural utilization. The country benefits from advanced diagnostic infrastructure, high healthcare expenditure, and widespread adoption of precision oncology technologies. More than 500,000 cancer cases are diagnosed annually in Germany, creating significant demand for minimally invasive biopsy procedures across breast, lung, prostate, and colorectal cancer diagnostics. Approximately 69% of German hospitals utilize image-guided biopsy systems integrated with digital imaging technologies. Ultrasound-guided procedures account for nearly 41% of minimally invasive interventions because of shorter procedural durations and high diagnostic efficiency. MRI-guided biopsy systems experienced approximately 26% higher adoption in tertiary oncology centers specializing in breast and prostate cancer diagnosis. Germany also demonstrates strong integration of AI-assisted pathology systems. 

UNITED KINGDOM Minimally Invasive Biopsy Techniques Market

The United Kingdom contributes approximately 18% of the Europe Minimally Invasive Biopsy Techniques Market Share due to rising cancer screening volumes and increasing adoption of image-guided diagnostic technologies. More than 390,000 cancer cases are diagnosed annually in the country, significantly increasing demand for minimally invasive tissue sampling procedures. Breast cancer diagnostics represent approximately 36% of total biopsy procedures performed across healthcare institutions in the United Kingdom. Nearly 64% of hospitals and oncology centers in the country utilize ultrasound-guided biopsy systems because of their procedural efficiency and lower complication rates. MRI-guided biopsy adoption increased by approximately 23% across tertiary healthcare facilities specializing in breast and prostate cancer diagnostics. Robotic-assisted biopsy systems are increasingly implemented across advanced oncology centers to improve lesion targeting accuracy and procedural precision. 

ASIA-PACIFIC

Asia-Pacific accounts for approximately 24% of the global Minimally Invasive Biopsy Techniques Market Share and represents one of the fastest-expanding regional markets due to rising healthcare investments, increasing cancer prevalence, and improving access to advanced diagnostic technologies. More than 8 million cancer cases are diagnosed annually across the Asia-Pacific region, significantly increasing demand for minimally invasive oncology diagnostics. China, Japan, India, and South Korea remain the leading contributors to regional procedural growth. Approximately 53% of tertiary hospitals across Asia-Pacific now utilize image-guided biopsy systems for breast, lung, liver, and prostate cancer diagnostics. Ultrasound-guided procedures contribute nearly 46% of total minimally invasive interventions because of cost efficiency and wider accessibility in developing healthcare systems. MRI-guided biopsy procedures also experienced approximately 25% higher adoption across advanced oncology institutions in Japan, China, and South Korea. 

JAPAN Minimally Invasive Biopsy Techniques Market

Japan represents a technologically advanced contributor to the Asia-Pacific Minimally Invasive Biopsy Techniques Market and accounts for approximately 19% of regional procedural utilization. The country maintains strong adoption of robotic-assisted and AI-integrated diagnostic technologies due to advanced healthcare infrastructure and increasing cancer screening participation. More than 1 million cancer cases are diagnosed annually in Japan, creating strong demand for minimally invasive oncology diagnostics. Approximately 68% of tertiary healthcare institutions in Japan utilize image-guided biopsy systems integrated with digital pathology platforms. Ultrasound-guided procedures account for nearly 42% of minimally invasive interventions, while MRI-guided biopsy procedures experienced approximately 26% higher adoption across advanced oncology centers. Breast and prostate cancer diagnostics remain the leading application areas for image-guided biopsy technologies. 

CHINA Minimally Invasive Biopsy Techniques Market

China represents one of the largest contributors to the Asia-Pacific Minimally Invasive Biopsy Techniques Market and accounts for approximately 36% of regional procedural utilization. Rapid healthcare infrastructure development, increasing cancer incidence, and expanding government-supported screening programs continue driving strong demand for minimally invasive biopsy procedures throughout the country. More than 4 million cancer cases are diagnosed annually in China, creating substantial procedural demand across oncology centers and tertiary hospitals. Approximately 57% of major hospitals in China utilize image-guided biopsy systems for breast, lung, liver, and colorectal cancer diagnostics. Ultrasound-guided biopsy procedures contribute nearly 48% of minimally invasive interventions because of operational affordability and broader availability across urban and semi-urban healthcare facilities. 

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 6% of the global Minimally Invasive Biopsy Techniques Market Share and continues to experience steady growth due to expanding healthcare infrastructure and increasing investments in oncology diagnostics. Rising cancer prevalence across Gulf Cooperation Council countries and South Africa significantly contributes to procedural demand for minimally invasive biopsy technologies. More than 1 million cancer cases are diagnosed annually across the region, strengthening the need for advanced diagnostic interventions. Approximately 44% of tertiary healthcare institutions across the Middle East & Africa now utilize image-guided biopsy systems for breast, liver, prostate, and lung cancer diagnostics. Ultrasound-guided procedures contribute nearly 49% of minimally invasive interventions because of wider accessibility and operational efficiency. MRI-guided biopsy systems are increasingly implemented across specialized oncology centers in the United Arab Emirates and Saudi Arabia. Governments across the region continue investing in cancer screening programs and digital healthcare infrastructure. 

List of Key Minimally Invasive Biopsy Techniques Market Companies

• F.Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• QIAGEN NV
• Guardant Health, Inc
• Veracyte, Inc
• Myriad Genetics, Inc
• Biocept, Inc
• NeoGenomics Laboratories, Inc
• Adaptive Biotechnologies Corporation

Top Two Companies with Highest Share

• F.Hoffmann-La Roche AG: Holds approximately 18% market share due to extensive oncology diagnostics portfolio and strong adoption of advanced tissue analysis technologies.
• Thermo Fisher Scientific, Inc.: Accounts for nearly 15% market share supported by broad molecular pathology integration and increasing utilization of automated biopsy diagnostic platforms.

Investment Analysis and Opportunities

The Minimally Invasive Biopsy Techniques Market continues attracting significant investment because healthcare providers increasingly prioritize precision diagnostics and outpatient oncology procedures. Approximately 48% of healthcare institutions globally increased investments in AI-assisted imaging systems and robotic-assisted biopsy technologies. Digital pathology integration projects expanded by nearly 36% across tertiary hospitals and specialized oncology centers. More than 52% of healthcare providers are prioritizing automated tissue characterization technologies to improve diagnostic accuracy and reduce procedural turnaround times. Investments in portable ultrasound-guided biopsy systems also increased substantially because outpatient diagnostic procedures expanded by approximately 41% globally.

Emerging economies present substantial Minimally Invasive Biopsy Techniques Market Opportunities because healthcare infrastructure investments continue accelerating across Asia-Pacific, Latin America, and Middle Eastern countries. Approximately 44% of public healthcare modernization initiatives now include digital imaging and minimally invasive oncology diagnostic upgrades. AI-enabled lesion detection systems improved procedural targeting efficiency by nearly 27%, encouraging further investment from private healthcare institutions and diagnostic imaging providers. Robotic-assisted biopsy procedures increased by approximately 33% across advanced oncology facilities, while precision medicine initiatives contributed to nearly 31% higher demand for tissue biomarker analysis linked with minimally invasive diagnostic workflows.

New Products Development

New product development within the Minimally Invasive Biopsy Techniques Market is increasingly focused on AI-integrated imaging systems, robotic-assisted navigation platforms, and portable biopsy technologies. Approximately 35% of newly introduced biopsy systems include automated lesion targeting software designed to improve tissue acquisition precision and reduce procedural errors. MRI-guided biopsy technologies experienced approximately 26% higher adoption because of enhanced imaging capabilities and improved soft tissue visualization. Portable ultrasound-guided biopsy systems also gained nearly 29% higher utilization across ambulatory care centers and rural healthcare facilities.

Manufacturers are increasingly prioritizing digital pathology integration and minimally invasive workflow optimization. Around 41% of newly launched biopsy instruments support real-time imaging analysis and automated specimen tracking systems. Vacuum-assisted biopsy technologies improved tissue extraction efficiency by approximately 24%, reducing repeat procedure requirements significantly. Robotic-assisted systems enhanced targeting precision by nearly 34% in complex oncology diagnostics including lung and prostate cancer interventions. Personalized oncology treatment programs continue encouraging development of high-accuracy tissue sampling technologies integrated with genomic profiling and biomarker analysis capabilities.

Five Recent Developments

• Advanced AI-guided biopsy platform launch: In 2024, several manufacturers introduced AI-enabled lesion targeting systems capable of improving procedural accuracy by approximately 28% while reducing diagnostic workflow delays by nearly 22%. Healthcare institutions increasingly integrated these platforms into digital pathology environments for oncology diagnostics.
• Expansion of robotic-assisted biopsy technologies: Robotic-assisted biopsy procedures increased by approximately 33% across tertiary oncology centers in 2024. Newly introduced robotic navigation systems improved tissue targeting precision by nearly 34% and reduced procedural variability during complex lung and prostate cancer interventions.
• Portable ultrasound-guided biopsy device introduction: Portable biopsy systems gained approximately 29% higher adoption across ambulatory surgical centers and rural healthcare networks in 2024. These systems improved outpatient procedural accessibility and reduced patient hospitalization requirements by nearly 31%.
• Digital pathology integration upgrades: Around 39% of pathology laboratories implemented advanced digital imaging and AI-supported tissue characterization systems during 2024. Automated pathology workflows improved reporting efficiency by approximately 24% and strengthened same-day diagnostic reporting capabilities.
• Vacuum-assisted biopsy technology enhancements: Newly developed vacuum-assisted biopsy systems improved tissue extraction consistency by nearly 26% while reducing repeat biopsy procedures by approximately 21%. Breast cancer diagnostics remained the leading application area for these advanced minimally invasive biopsy technologies in 2024.

Report Coverage Of Minimally Invasive Biopsy Techniques Market

The Minimally Invasive Biopsy Techniques Market Report provides comprehensive analysis of market trends, segmentation, technological advancements, regional outlook, and competitive dynamics influencing global industry expansion. The report evaluates procedural utilization patterns across image-guided biopsy technologies including ultrasound-guided, MRI-guided, CT-guided, and robotic-assisted systems. Approximately 61% of healthcare institutions globally now utilize image-guided biopsy procedures for oncology diagnostics, creating substantial demand for advanced tissue sampling technologies. The report also analyzes procedural adoption across breast, prostate, lung, liver, and colorectal cancer diagnostics.

The report further examines healthcare infrastructure development, outpatient diagnostic expansion, AI-assisted imaging integration, and digital pathology implementation across major regions including North America, Europe, Asia-Pacific, and the Middle East & Africa. Nearly 48% of healthcare providers globally prioritize AI-enabled biopsy workflows to improve procedural targeting precision and diagnostic efficiency. Robotic-assisted biopsy technologies improved lesion localization accuracy by approximately 34%, while same-day diagnostic reporting capabilities expanded by nearly 24% across advanced oncology institutions. The Minimally Invasive Biopsy Techniques Market Research Report also provides detailed insights into competitive positioning, emerging product development strategies, investment opportunities, and evolving precision oncology trends shaping the future of minimally invasive diagnostics.